BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023, at 4:30 p.m. EST / 1:30 p.m. PST. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
| Presentation details: | |
| Date: | Monday, January 9, 2023 |
| Time: | 1:30 – 2:10 p.m. Pacific Standard Time (PST) |
| Moderator: | Eric Joseph, Ph.D. |
| Location: | Borgia Room, Westin St. Francis Hotel, San Francisco |
| HilleVax Participant: | Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer |
| Webcast & Audio Visual: | https://jpmorgan.metameetings.net/events/healthcare23/sessions/43891-hillevax/webcast?gpu_only=true&kiosk=true |
About HilleVax
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a VLP based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.
Contact:
Shane Maltbie
[email protected]
+1-617-213-5054
